Beijing Aitaipu Biomedical Technology

Beijing Aitaipu Biomedical Technology is an innovative biotechnology company based in China that specializes in the discovery and development of small molecule therapeutics targeting the purinergic signaling system. The company's research is centered on the biological role of adenosine triphosphate (ATP) and its receptors, particularly the P2X7 receptor, in mediating inflammatory and immune responses. By developing potent and selective modulators of these pathways, Aitaipu aims to address significant unmet medical needs in chronic pain, neuroinflammation, and various cancers. Founded in 2021, the firm leverages a deep understanding of purinergic pharmacology to advance its pipeline through early-stage drug discovery toward clinical validation. The company is strategically located in Beijing's pharmaceutical development hub to facilitate collaborations and rapid growth.